Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00828373
Other study ID # CER 08 - 202
Secondary ID Swissmedic
Status Completed
Phase Phase 4
First received January 22, 2009
Last updated July 14, 2011
Start date August 2009
Est. completion date August 2010

Study information

Verified date August 2009
Source University Hospital, Geneva
Contact n/a
Is FDA regulated No
Health authority Switzerland: Swissmedic
Study type Interventional

Clinical Trial Summary

Lidocaine is a local anesthetic which is widely used in daily anesthesia and surgical practice. It has been shown that intravenous lidocaine given during an operation has analgesic properties. Finally intravenous lidocaine is inexpensive and easy to administer and safe if non-toxic doses are respected. It is likely that the use of lidocaine infusions during anesthesia might increase in the coming years. Neuromuscular blockers (curare like substances) are used in anesthesia to facilitate tracheal intubation and to achieve muscle relaxation and immobility during surgery. Rocuronium is one of the most widely used neuromuscular blocking agents. Local anesthetics, such as lidocaine, are known to potentiate the effect of neuromuscular blocking agents. In the study the investigators want to evaluate the effect of intravenous lidocaine during the operation on the time course of the rocuronium-induced neuromuscular block. A secondary aim is to evaluate intubation conditions (lidocaine has been shown also to improve intubation conditions) and safety.


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date August 2010
Est. primary completion date August 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Adult, age =18 to 60 years, male or female.

- American Society of Anesthesiology [ASA] status I or II.

- Patient is able to read and understand the information sheet and to sign and date the consent form.

- Patient scheduled of elective surgery lasting longer than 120 min without need for continuous curarisation.

- Surgery without application of local anesthetics (epidurals, wound-infiltration).

- If the patient is female and of childbearing potential, she must have a negative pregnancy test.

Exclusion Criteria:

- A history of allergy or hypersensitivity to rocuronium or lidocaine

- Neuromuscular disease

- Preoperative medications known to influence neuromuscular function (for instance, certain antibiotics [aminoglycosides] and anticonvulsants [phenytoine])

- Electrolyte abnormalities (for instance, hypermagnesemia)

- Hepatic or renal insufficiency

- Patients with epileptic disease

- Patients with a body mass index <19 or >28 kg m2

- Pregnant or breastfeeding women

- Expected difficult intubation or mask ventilation

- Atrioventricular heart block II or III -

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Placebo
Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the Placebo group this will be physiologic saline. The infusion will be stopped after complete recovery from the neuromuscular block.
Lidocaine
Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the lidocaine Arm this regimen corresponds to 1.5 mg kg-1 lidocaine bolus injection and 2 mg kg-1 h-1 lidocaine continuous infusion. The infusion will be stopped after complete recovery from the neuromuscular block.

Locations

Country Name City State
Switzerland University Hospitals of Geneva Geneva

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Geneva

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Onset and recovery of the neuromuscular block From start of injection of rocuronium until TOF 90% No
Secondary To evaluate intubation conditions at T1, we will use the scale according to the Good Clinical Research practice (GRCP) in neuromuscular research 2 to 3 minutes No
Secondary Any minor adverse event (no need for intervention) or major adverse event will be recorded. up to 5 hours Yes
See also
  Status Clinical Trial Phase
Completed NCT02484651 - Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade? Phase 4
Completed NCT01440933 - Efficacy of Sugammadex in Magnesium Pretreated Patients Phase 2
Recruiting NCT02778945 - Neuromuscular Blockade for Optimising Surgical Conditions During Spinal Surgery Phase 4
Recruiting NCT02966249 - Dexmetomidine Intrathecally and Intravenously Additionally to Spinal Anaesthesia, in Total Knee Arthroplasty Phase 4
Completed NCT02838134 - Deep Versus Moderate Muscle Relaxation During Laparoscopic Donor Nephrectomy in Enhancing Postoperative Recovery Phase 4
Completed NCT03734250 - D Vitamin Effects on Neuromuscular Blocker Reverse Time
Not yet recruiting NCT03287388 - MRI Measurement of the Effects of Deep Neuromuscular Blockade on the Abdominal Working Space During Laparoscopy N/A
Completed NCT01791036 - Adductor Canal Block In Anterior Cruciate Ligament (ACL) Repair N/A
Not yet recruiting NCT02648503 - Deep Neuromuscular Block and Sugammadex Versus Standard of Care on Quality of Recovery in Patient Undergo Elective Laparoscopic Cholecystectomy Phase 4
Completed NCT00895609 - Sugammadex and Neostigmine at Shallow Neuromuscular Blockade Phase 4
Completed NCT02483611 - Effects of Intravenous Lidocaine Associated With Magnesium Sulfate on the Cisatracurium-Induced Neuromuscular Block Phase 4
Completed NCT02320734 - Deep Neuromuscular Relaxation in Patients for Thoraco-laparoscopic Esophagectomy Phase 4
Recruiting NCT05005676 - Evaluation of the New Acceleromyograph TOF 3D N/A
Not yet recruiting NCT03460509 - Reversal With Low Doses of Sugammadex in Patients Undergoing Non-cardiac Surgery Phase 4